Affinage

PDE6A

Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha · UniProt P16499

Length
860 aa
Mass
99.5 kDa
Annotated
2026-04-29
32 papers in source corpus 11 papers cited in narrative 10 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

PDE6A encodes the α-catalytic subunit of the rod photoreceptor cGMP phosphodiesterase-6 heterotetrameric complex (PDE6αβγγ), which hydrolyzes cGMP during phototransduction with Km ~20 µM and kcat ~4500 s⁻¹ in response to transducin activation (PMID:20940301). PDE6A is enzymatically equivalent to PDE6B, but the native heterodimer requires higher transducin concentrations for activation than homodimeric forms; PDE6A expression is essential for the stability and expression of PDE6B and PDE6G subunits, such that loss of PDE6A abolishes PDE6 complex integrity and enzymatic activity (PMID:20940301, PMID:18775863). Loss-of-function mutations in PDE6A cause cGMP accumulation, PARP activation, and calpain-mediated (non-apoptotic) photoreceptor cell death, with degeneration severity being allele-dependent; these mutations underlie autosomal recessive retinitis pigmentosa, and gene supplementation via AAV restores rod function and photoreceptor survival in canine models (PMID:26188004, PMID:27551530, PMID:29212382).

Mechanistic history

Synthesis pass · year-by-year structured walk · 8 steps
  1. 2001 Medium

    Establishing that PDE6A transcription is photoreceptor-restricted answered where in the body this gene is relevant and enabled later targeted therapeutic strategies.

    Evidence Transgenic mice expressing reporter under PDE6A upstream promoter fragment; RT-PCR across tissues

    PMID:11401494

    Open questions at the time
    • Minimal promoter elements and transcription factor binding sites not mapped
    • Brain expression not functionally characterized
  2. 2008 High

    Demonstrating that PDE6A protein is required for stability of PDE6B and PDE6G established that PDE6A is not merely catalytic but serves a structural scaffolding role within the heterotetrameric complex.

    Evidence Western blot, enzymatic assay, and immunohistochemistry in PDE6A-mutant dog and ENU-mutagenized mouse retinas

    PMID:18775863 PMID:18849587

    Open questions at the time
    • Mechanism of PDE6A-dependent stabilization of PDE6B/PDE6G not defined at a structural level
    • Whether PDE6B reciprocally stabilizes PDE6A not tested
  3. 2010 High

    Showing that PDE6A and PDE6B catalytic domains are enzymatically equivalent resolved a long-standing question about why phototransduction requires a heterodimer, shifting focus to the heterodimer's unique transducin-sensitivity properties.

    Evidence Chimeric homodimeric PDE6 enzymes expressed in transgenic Xenopus; in vitro kinetics and transducin activation assays

    PMID:20940301

    Open questions at the time
    • Structural basis for differential transducin sensitivity of heterodimer versus homodimer unknown
    • Whether heterodimer asymmetry affects PDE6γ inhibition stoichiometry not resolved
  4. 2015 High

    Identifying calpain-mediated, caspase-independent cell death as the execution pathway downstream of PDE6A mutations clarified the non-apoptotic mechanism of photoreceptor degeneration and revealed allele-dependent severity.

    Evidence Multiple Pde6a point-mutant and compound-heterozygous mouse lines; cGMP immunostaining, calpain/caspase activity assays, ERG, retinal morphometry

    PMID:26188004

    Open questions at the time
    • Exact link between cGMP accumulation and calpain activation not molecularly defined
    • Contribution of cGMP-gated channel overactivation versus direct cGMP-dependent kinase signaling not dissected
  5. 2016 Medium

    Demonstrating causal involvement of PARP in PDE6A-deficient photoreceptor death and showing allele-dependent neuroprotection by PARP inhibition positioned PARP as a druggable node in the degeneration cascade.

    Evidence PARP activity assays in Pde6a mutant retinas; organotypic retinal explants treated with PARP inhibitor PJ34

    PMID:27551530

    Open questions at the time
    • In vivo efficacy of PARP inhibition not demonstrated
    • Whether PARP acts upstream or parallel to calpain not resolved
    • Single lab, single pharmacological tool
  6. 2016 Medium

    Finding that PDE6A-null patients have doubled plasma cGMP revealed a systemic metabolic consequence of retinal PDE6A loss, indicating rod photoreceptors contribute measurably to whole-body cGMP homeostasis.

    Evidence Plasma cGMP immunoassay in patients with homozygous PDE6A splice-site mutation versus controls

    PMID:27820873

    Open questions at the time
    • Small cohort size limits generalizability
    • Functional significance of elevated systemic cGMP not explored
    • Single immunoassay method
  7. 2017 High

    AAV-mediated PDE6A gene supplementation in a large animal model restored rod function, preserved photoreceptor structure, and re-established PDE6B expression, providing preclinical proof-of-concept for gene therapy.

    Evidence Subretinal AAV injection in Pde6a-mutant dogs; ERG, dim-light vision testing, OCT, histology, immunohistochemistry for PDE6 subunits and cGMP

    PMID:28676737 PMID:29212382

    Open questions at the time
    • Long-term durability of rescue not established
    • Optimal therapeutic window relative to degeneration stage not defined
  8. 2024 Medium

    Prime editing achieved precise correction of a Pde6a point mutation in vivo without bystander editing, and Nrl inactivation-mediated rod-to-cone reprogramming independently rescued PDE6A-deficient retinas, establishing both mutation-specific and gene-independent therapeutic paradigms.

    Evidence Dual AAV prime editing and AAV-SaCas9 Nrl disruption in Pde6a mutant mice; sequencing, Western blot, ERG, histology

    PMID:39297417 PMID:39499900

    Open questions at the time
    • Prime editing efficiency (~9.4%) may be insufficient for clinical translation
    • Long-term safety and off-target profiling of both approaches incomplete
    • Whether rod-to-cone reprogramming preserves normal visual processing unknown

Open questions

Synthesis pass · forward-looking unresolved questions
  • The structural basis for the heterotetrameric PDE6 complex's unique transducin sensitivity, the molecular link between cGMP accumulation and calpain/PARP activation, and the interplay between PDE6A and PDE6B in complex assembly remain unresolved.
  • No high-resolution structure of the full native PDE6 heterotetramer with transducin
  • Precise signal from cGMP overload to PARP and calpain not molecularly mapped
  • Whether PDE6A has functions outside of the PDE6 complex is unknown

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0016787 hydrolase activity 2
Pathway
R-HSA-9709957 Sensory Perception 4 R-HSA-5357801 Programmed Cell Death 2 R-HSA-162582 Signal Transduction 1
Partners
PDE6BPDE6G
Complex memberships
rod PDE6 heterotetramer (PDE6A/PDE6B/PDE6G₂)

Evidence

Reading pass · 10 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2010 PDE6A and PDE6B catalytic subunits are enzymatically equivalent: chimeric homodimeric enzymes containing PDE6A or PDE6B catalytic domains hydrolyze cGMP with similar Km (~20-23 μM) and kcat (~4200-5100 s⁻¹) values, and show comparable Ki values for inhibition by PDE6 γ-subunits (Pγ). Both are fully activated by recombinant cone transducin-α (Gαt2) and native rod Gαt1, but rod PDE6 heterodimer requires markedly higher concentrations of transducin for half-maximal activation compared to the homodimeric forms. Expression of chimeric EGFP-PDE6C-A and EGFP-PDE6C-B in transgenic Xenopus laevis, selective immunoprecipitation, in vitro enzymatic assay measuring cGMP hydrolysis kinetics and transducin activation The Journal of biological chemistry High 20940301
2008 PDE6A protein is essential for normal expression and stability of PDE6B and PDE6G subunits: affected dog retinas lacking PDE6A protein also lacked PDE6B and PDE6G, and had no PDE6 enzymatic activity, demonstrating that PDE6A expression is required for the integrity of the heterotetrameric PDE6 complex. Western blot analysis of retinal extracts from PDE6A mutant dogs; enzymatic activity assay for PDE6; immunohistochemistry Investigative ophthalmology & visual science High 18775863
2008 Missense mutations in the catalytic domain of PDE6A not only impair PDE6A function but also reduce PDE6B levels within the retina, revealing previously unrecognized structure-function relationships and allelic variation affecting the stability of the PDE6 complex. Genetic positional candidate cloning in ENU-mutagenized mice; biochemical analysis of PDE6 subunit levels in mutant retinas Human molecular genetics Medium 18849587
2015 Different PDE6A point mutations (V685M, R562W, D670G) cause distinct rates of photoreceptor degeneration with accumulation of cGMP, increased calpain activity, but not increased caspase activity, indicating non-apoptotic (calpain-mediated) cell death execution downstream of PDE6A loss of function. Compound heterozygous Pde6a V685M/R562W animals show intermediate phenotype severity. Mouse models with homozygous and compound heterozygous Pde6a mutations; cGMP immunostaining, calpain and caspase activity assays, in vivo ERG, retinal morphology, photoreceptor cell death assays Human molecular genetics High 26188004
2016 PARP is activated downstream of PDE6A loss-of-function mutations and causally contributes to photoreceptor cell death; PARP inhibition with PJ34 in organotypic retinal explants is neuroprotective, with efficacy inversely correlating with mutation severity (D670G > R562W > V685M/R562W > V685M). PARP activity assays in Pde6a mutant mouse retinas; organotypic retinal explant culture treated with PARP inhibitor PJ34; multiple treatment time points and durations Cell death discovery Medium 27551530
2001 A short upstream fragment of the PDE6A gene functions as a promoter that drives transcription predominantly in retinal photoreceptors and weakly in brain, but not in heart, kidney, liver, or lung. Transgenic mice expressing reporter transgene under PDE6A upstream fragment; RT-PCR analysis of tissue-specific expression across four transgenic lines Biochemical and biophysical research communications Medium 11401494
2017 AAV-mediated PDE6A gene supplementation in Pde6a mutant dogs restores rod photoreceptor function (ERG responses, dim-light vision), preserves photoreceptor layer thickness, restores cGMP homeostasis, improves rod opsin localization to outer segments, reduces Müller cell activation, and rescues bipolar cell dendrite distribution; treatment also resulted in re-expression of Pde6b in rod outer segments. Subretinal AAV injection in Pde6a mutant dogs; ERG, vision testing, OCT, histology, immunohistochemistry for transgene expression, cGMP levels, opsin localization, bipolar cell markers Human gene therapy High 28676737 29212382
2016 Patients with homozygous PDE6A loss-of-function mutations (IVS6+1G>A) have approximately twice the plasma cGMP levels compared to controls, demonstrating that PDE6A-mediated cGMP hydrolysis in rod photoreceptors contributes measurably to systemic cGMP homeostasis. Immunoassay measurement of plasma cGMP levels in patients with confirmed homozygous PDE6A splice-site mutations versus controls Investigative ophthalmology & visual science Medium 27820873
2024 Base editing and prime editing can correct the Pde6a D670G point mutation in mouse retina; optimized prime editing via dual AAV delivery achieves ~9.4% correction efficiency, restores PDE6A protein expression, preserves photoreceptors, and rescues retinal function in Pde6a mutant mice with no detectable bystander editing. Screening of BE and PE systems in N2a cells; dual AAV delivery of PE into mouse retina; sequencing for editing efficiency and bystander effects; Western blot for PDE6A protein; ERG and histology for functional/structural rescue Advanced science Medium 39297417
2024 AAV-SaCas9-mediated inactivation of Nrl (a rod transcription factor) in Pde6a-deficient mice prevents retinal degeneration and rescues retinal function, demonstrating that rod-to-cone photoreceptor identity reprogramming is a viable gene-independent therapeutic strategy downstream of PDE6A loss. All-in-one AAV-SaCas9 delivery of Nrl-targeting sgRNA into Pde6anmf363/nmf363 mouse retina; sgRNA screening in N2a cells; in vivo photoreceptor survival and ERG functional assessment JCI insight Medium 39499900

Source papers

Stage 0 corpus · 32 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2008 New mouse models for recessive retinitis pigmentosa caused by mutations in the Pde6a gene. Human molecular genetics 63 18849587
2008 Characterization of a canine model of autosomal recessive retinitis pigmentosa due to a PDE6A mutation. Investigative ophthalmology & visual science 49 18775863
2015 Retinitis pigmentosa: impact of different Pde6a point mutations on the disease phenotype. Human molecular genetics 43 26188004
2010 Rod phosphodiesterase-6 PDE6A and PDE6B subunits are enzymatically equivalent. The Journal of biological chemistry 43 20940301
2017 Gene Therapy in a Large Animal Model of PDE6A-Retinitis Pigmentosa. Frontiers in neuroscience 39 28676737
2017 Gene Supplementation Rescues Rod Function and Preserves Photoreceptor and Retinal Morphology in Dogs, Leading the Way Toward Treating Human PDE6A-Retinitis Pigmentosa. Human gene therapy 32 29212382
2015 Splice-site mutations identified in PDE6A responsible for retinitis pigmentosa in consanguineous Pakistani families. Molecular vision 21 26321862
2017 Gene Therapy Successfully Delays Degeneration in a Mouse Model of PDE6A-Linked Retinitis Pigmentosa (RP43). Human gene therapy 20 29212391
2016 Efficacy of PARP inhibition in Pde6a mutant mouse models for retinitis pigmentosa depends on the quality and composition of individual human mutations. Cell death discovery 20 27551530
2020 Clinical Phenotype and Course of PDE6A-Associated Retinitis Pigmentosa Disease, Characterized in Preparation for a Gene Supplementation Trial. JAMA ophthalmology 16 33057649
2008 Enzymatic characteristics of two novel Myxococcus xanthus enzymes, PdeA and PdeB, displaying 3',5'- and 2',3'-cAMP phosphodiesterase, and phosphatase activities. FEBS letters 15 19114044
2000 Exclusion of the PDE6A gene for generalised progressive retinal atrophy in 11 breeds of dog. Animal genetics 14 10782214
2024 Efficient Rescue of Retinal Degeneration in Pde6a Mice by Engineered Base Editing and Prime Editing. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 13 39297417
2001 A PDE6A promoter fragment directs transcription predominantly in the photoreceptor. Biochemical and biophysical research communications 13 11401494
2006 Contribution of the cyclic nucleotide phosphodiesterases PdeA and PdeB to adaptation of Myxococcus xanthus cells to osmotic or high-temperature stress. Journal of bacteriology 12 16385075
2022 Central Visual Function and Genotype-Phenotype Correlations in PDE6A-Associated Retinitis Pigmentosa. Investigative ophthalmology & visual science 11 35533076
2022 Novel variants in PDE6A and PDE6B genes and its phenotypes in patients with retinitis pigmentosa in Chinese families. BMC ophthalmology 9 35033039
2016 Increased Plasma cGMP in a Family With Autosomal Recessive Retinitis Pigmentosa Due to Homozygous Mutations in the PDE6A Gene. Investigative ophthalmology & visual science 9 27820873
2019 Advancing Gene Therapy for PDE6A Retinitis Pigmentosa. Advances in experimental medicine and biology 8 31884596
2019 Establishment and characterization of an iPSC line (FRIMOi001-A) derived from a retinitis pigmentosa patient carrying PDE6A mutations. Stem cell research 7 30685614
2024 PDE6A-Associated Retinitis Pigmentosa, Clinical Characteristics, Genetics, and Natural History. Ophthalmology. Retina 6 39218074
2021 A new PDE6A missense variant p.Arg544Gln in rod-cone dystrophy. Documenta ophthalmologica. Advances in ophthalmology 6 33611760
2017 Novel PDE6A mutation in an Emirati patient with retinitis pigmentosa. Oman journal of ophthalmology 6 29118501
2021 PdeA is required for the rod shape morphology of Brucella abortus. Molecular microbiology 4 34662460
2021 Novel mutations in PDE6A and CDHR1 cause retinitis pigmentosa in Pakistani families. International journal of ophthalmology 4 34926197
2021 P.arg102ser is a common Pde6a mutation causing autosomal recessive retinitis pigmentosa in Pakistani families. JPMA. The Journal of the Pakistan Medical Association 2 34057927
2000 Characterization of a cDNA encoding RP43, a CUB-domain-containing protein from the tube of Riftia pachyptila (Vestimentifera), and distribution of its transcript. The Biochemical journal 2 10947956
2019 Sildenafil Administration in Dogs Heterozygous for a Functional Null Mutation in Pde6a: Suppressed Rod-Mediated ERG Responses and Apparent Retinal Outer Nuclear Layer Thinning. Advances in experimental medicine and biology 1 31884640
2026 Safety and vision outcomes of subretinal gene supplementation therapy in PDE6A-associated retinitis pigmentosa: a non-randomised controlled trial. The British journal of ophthalmology 0 40825661
2024 All-in-one AAV-mediated Nrl gene inactivation rescues retinal degeneration in Pde6a mice. JCI insight 0 39499900
2024 Cortex Dictamni induces retinitis pigmentosa in zebrafish by inhibiting pde6a post-transcriptional activity via mmu-mir-6240-p3_2. Journal of ethnopharmacology 0 39716511
2018 Co-Existence of Novel PDE6A Mutations and A Recurrent RPGR Mutation: A Potential Explanation for Phenotypic Diversity in Female RPGR Mutation Carriers. Current molecular medicine 0 30289068